Enoxaparin, a low-molecular-weight heparin suppresses prothrombin activation more effectively than unfractionated heparin in patients treated for venous thromboembolism

Thrombosis Research

Volumn 86, Issue 5, 1997, Pages 349-354

  Grosset, Alan B ^a   Spiro, Theodore E ^c   Beynon, Julia ^a   Rodgers, George M ^a,b  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c SANOFI   (France)

Author keywords

Enoxaparin; Heparin; Low molecular weight heparin; Thrombosis

Indexed keywords

ANTITHROMBIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PEPTIDE FRAGMENT; THROMBIN;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOEMBOLISM; VEIN THROMBOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ANTITHROMBIN III; ENOXAPARIN; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PEPTIDE HYDROLASES; PROTHROMBIN; SAFETY; THROMBOEMBOLISM;

EID: 0030790774     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(97)00079-0     Document Type: Article

References (15)

1. HYERS TN, HULL RD, WEG JG. Antithrombotic therapy for venous thromboembolic disease. Chest 102 (Suppl), 408s-425s, 1992.
2. HIRSH J. Heparin. N Engl J Med 324, 1565-1574, 1991.
3. HIRSH J, LEVINE MN. Low molecular weight heparin. Blood 79, 1-17, 1992.
4. HYERS TM, HULL RD, WEG JG. Antithrombotic therapy for venous thromboembolic disease. Chest 108 (Suppl), 335s-351s, 1995.
5. BUCKLEY MA, SORKIN EM. Enoxaparin: A review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders. Drugs 44, 465-497, 1992.
6. HUET Y, JANVIER G, BENDRISS PH, et al. Treatment of established venous thromboembolism with enoxaparin: Preliminary report. Acta Chir Scand 556 (Suppl 1), 116-120, 1990.
7. PARENT F, COLLIGNON F, DARNE B, et al. Treatment of venous thrombo-embolism with a daily subcutaneous injection of enoxaparin: Preliminary results of a pharmacokinetic study. Thromb Haemost 69, 860, 1993.
8. LEVINE M, GENT M, HIRSH J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 334, 677-681, 1996.
9. ALBADA J, NIEUWENHUIS HK, SIXMA JJ. Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin): Results of a double- blind randomized study. Circulation 80, 935-940, 1989.
10. LOPACIUK S, MEISSNER AJ, FILIPECKI S, et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: A Polish multicenter trial. Thromb Haemost 68, 14-18, 1992.
11. A Collaborative European Multicentre Study. A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 65, 251-256, 1991.
12. SIMONNEAU G, CHARBONNIER B, DECOUSUS H, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal vein thrombosis. Arch Intern Med 153, 1541-1546, 1993.
13. LENSING AWA, PRINS MH, DAVIDSON BL, HIRSH J. Treatment of deep venous thrombosis with low-molecular-weight heparins. Arch Intern Med 155, 601-607, 1995.
14. LEIZOROVICZ A, SIMONNEAU G, DECOUSUS H, BOISSEL JP. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: A meta-analysis. Br Med J 309, 299-304, 1994.
15. The DVTENOX Study Group. Markers of hemostatic system activation in acute deep venous thrombosis-Evolution during the first days of heparin treatment. Thromb Haemost 70, 909-914, 1993.